- Fellowship - Stanford University Hospital (1983-1985), Gynecologic Oncology
- Fellowship - University of California at San Diego (1981-1982), Gynecologic Oncology
- Residency - Medical College of Pennsylvania (1978-1981), Obstetrics & Gynecology
- Internship - Medical College of Pennsylvania (1977-1978), Obstetrics & Gynecology
- Medical School - University of Oklahoma at Tulsa

David Scott Miller, M.D.
- Dallas Foundation Chair in Gynecologic Oncology
- Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
- Obstetrics and Gynecology - Gyn Oncology
- Gynecologic Cancers
- Surgical Treatment for Gynecologic Cancer
Biography
David Scott Miller, M.D., is a Professor in the Department of Obstetrics and Gynecology at UT Southwestern Medical Center. He specializes in cancers of the female reproductive system and serves as Medical Director for the Division of Gynecologic Oncology's practice at both the Harold C. Simmons Comprehensive Cancer Center and Parkland Health and Hospital System.
Dr. Miller earned his medical degree at the University of Oklahoma–Tulsa and completed a residency in obstetrics and gynecology at the Medical College of Pennsylvania. He received advanced training through a reproductive endocrinology fellowship at the University of California, San Diego and a gynecologic oncology fellowship at Stanford University Medical Center.
Board certified in obstetrics and gynecology and gynecologic oncology, he joined the UT Southwestern faculty in 1991.
Dr. Miller serves as principal investigator for the National Cancer Institute’s Gynecologic Oncology Group program at UT Southwestern. He also is an examiner for the American Board of Obstetrics and Gynecology, where he participates in the oral examination of physicians seeking certification as specialists in gynecologic oncology.
Dr. Miller’s research interests include reconstructive pelvic surgery, gynecologic oncology, and clinical trials. He has published several academic articles.
He is frequently included in D Magazine’s list of Best Doctors in Dallas and as a Super Doctor in Texas Monthly magazine.
Dr. Miller is a member of the Society of Gynecologic Oncology, the American Society of Clinical Oncology, the American College of Obstetricians and Gynecologists, and the American College of Surgeons.
Meet Dr. Miller
Gynecologic Oncology Specialist in Dallas
Early in his career, David Scott Miller, M.D., decided that his mission was helping women with their journey through cancer. He believes that no matter what the cancer diagnosis is, it brings a sense of urgency and clarity. That belief is part of the driving force behind his nationally and internationally recognized work to improve the evaluation and treatment of gynecologic cancers.
"When and where the cancer is diagnosed will have an impact on a woman’s chances of surviving the disease. It’s extremely important to have one doctor trained in all aspects of evaluating and treating gynecologic cancer committed to the patient," he says.
Since joining UT Southwestern Medical Center in 1991, Dr. Miller has assembled a team focused completely on gynecologic cancers. This team includes faculty physicians – trained and board certified in obstetrics and gynecology – who have gone on to complete fellowship training in gynecologic oncology. They are experts in gynecology and the cancers that affect the female reproductive organs and are passionate about caring for women with gynecologic cancer.
Cancers affecting a woman’s reproductive system, including the ovaries, uterus, cervix, vagina, vulva, and placenta, can be complex. Dr. Miller and his team bring a comprehensive approach to care that offers patients unique access to the newest diagnostic procedures, innovative therapies and surgical care, exceptional support services, and groundbreaking research and clinical trials.
An advocate of providing the newest options to patients, Dr. Miller says UT Southwestern is on the leading edge of surgical and medical innovations to eliminate gynecologic cancer. These innovations include state-of-the-art minimally invasive and robotic procedures to remove tumors, fertility-sparing procedures, and targeted therapies to attack cancer cells without damaging noncancerous tissue.
Dr. Miller serves as a principal investigator for the National Cancer Institute’s Gynecologic Oncology Group and participates in the cancer evaluation and treatment protocols developed by that organization. UT Southwestern is also the only institution in North Texas that is a member of the National Institutes of Health’s (NIH) Gynecologic Oncology Group, which is the hub of major research and innovations for gynecologic cancers.
Education & Training
Professional Associations & Affiliations
- Society of Gynecologic Oncology
- Gynecologic Oncology Group
- American Society of Clinical Oncology
- American College of Surgeons
- American College of Obstetricians & Gynecologists
Honors & Awards
- Super Doctors in Texas - Oncology 2004-2024, Oncology; Obstetrics/Gynecology
- D Magazine Best Doctor 2010-2022
- Top Doctor - Gynecologic Oncology / Gynecology 2013, U.S. News and World Report
- Texas Super Doctors 2011, Texas Monthly
- Senior Residents Award for Outstanding Faculty Teacher 2000, Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center at Dallas
- National Faculty Award 2000, Council on Resident Education in Obstetrics & Gynecology
- First Prize Scientific Paper Award 1991, American College of Obstetricians & Gynecologists, 39th Annual Meeting
Books & Publications
-
Publications
-
Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma
Vintzileos W, Beer H, Miller D, Lea J Gynecologic Oncology Reports 2025 Apr 58 -
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
Matei DE, Enserro DM, Randall ME, Mutch D, Small W, Disilvestro PA, Spirtos NM, O'Malley DM, Cantuaria GH, Michelin D, Waggoner S, Shahin M, Guntupalli S, Lara O, Ueland FR, Warshal D, Bonebrake A, Tewari KS, Tan A, Powell MA, Walker JL, Santin AD, Kim JH, Miller DS Journal of Clinical Oncology 2025 Mar 43 1055-1060 -
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258
Clements A, Enserro D, Strickland KC, Previs R, Matei D, Mutch D, Powell M, Klopp A, Miller DS, Small W, DiSilvestro P, Spirtos N, Cosgrove C, Sfakianos G, Liu JR, Vargas R, Shahin M, Corr B, Dessources K, Ueland F, Warshal D, Gillen J, Secord AA Gynecologic oncology 2025 Feb 193 119-129 -
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14
Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM Gynecologic oncology 2024 Nov 190 283-290 -
NCCN GUIDELINES® INSIGHTS CE Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, Barroilhet L, Uppal S, Hendrickson AW, Gershenson DM, Gray HJ, Hakam A, Jain A, Konecny GE, Moroney J, Ratner E, Schorge J, Thaker PH, Werner TL, Zsiros E, Behbakht K, Chen LM, DeRosa M, Eisenhauer EL, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez RD, Armstrong DK JNCCN Journal of the National Comprehensive Cancer Network 2024 Oct 22 512-519 -
Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer
Walker CA, Edwards C, McIntire D, Makepeace L, Holloway SB, Kakadiaris E, Spirtos AN, Miller DS, Lea JS Gynecologic oncology 2024 Sep 188 22-26 -
Radiation Therapy with or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results from an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial
Klopp AH, Enserro D, Powell M, Randall M, Schink JC, Mannel RS, Holman L, Bender D, Kushnir CL, Backes F, Zweizig SL, Waggoner S, Bradley KA, Lawrence LD, Hanjani P, Darus CJ, Small W, Cardenes HR, Feddock JM, Miller DS Journal of Clinical Oncology 2024 Jul 42 2425-2435 -
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279
Horowitz NS, Deng W, Peterson I, Mannel RS, Thompson S, Lokich E, Myers T, Hanjani P, O'Malley DM, Chung KY, Miller DS, Ueland FR, Dizon DS, Miller A, Mayadev JS, Leath CA, Monk BJ Journal of Clinical Oncology 2024 Jun 42 1914-1921 -
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Regináčová K, Richardson DL, Perri T, Oza AM, Miller DS, Alía EM, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednaříková M, Chon HS, Martínez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Fariñas-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I Gynecologic oncology 2024 Jun 185 202-211 -
Social determinants of health in uterine carcinosarcoma
Aroche Gutierrez LL, McIntire DD, Lea J, LoCoco S, Miller DS Gynecologic oncology 2024 May 184 117-122 -
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer
Author Collaboration tE, Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V Journal of Clinical Oncology 2023 Dec 41 5400-5410 -
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice
Lorusso D, Colombo N, Herraez AC, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay SE, Ray-Coquard IL, Shapira-Frommer R, Kim YM, McCormack M, Massaad R, Nguyen AM, Zhao Q, McKenzie J, Prabhu VS, Makker V European Journal of Cancer 2023 Jun 186 172-184 -
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Makker V, Colombo N, Herráez AC, Monk BJ, MacKay H, Santin AD, Miller DS, Moore RG, Baron-Hay S, Ray-Coquard I, Ushijima K, Yonemori K, Kim YM, Guerra Alia EM, Sanli UA, Bird S, Orlowski R, McKenzie J, Okpara C, Barresi G, Lorusso D Journal of Clinical Oncology 2023 Jun 41 2904-2910 -
Isolated para-aortic nodal recurrence after treatment of early stage cervical carcinoma
Holloway SB, Mercadel AJ, Miller DS, Lea JS Gynecologic oncology 2023 Mar 170 248-253 -
Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment
Vergote I, Macarulla T, Hirsch FR, Hagemann C, Miller DS Cancers 2023 Feb 15 -
Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma
Walker CA, Spirtos AN, Miller DS Expert Review of Anticancer Therapy 2023 23 361-368 -
Adenocarcinoma of the uterine corpus and sarcomas of the uterus
Creasman WT, Miller DS, Eskander RN, Powell M 2023 Jan 125-174 -
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women with Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study
Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, O'Malley DM, Street DG, Tewari KS, Bender DP, Morris RT, Lowery WJ, Miller DS, Dewdney SB, Spirtos NM, Lele SB, Guntupalli S, Ueland FR, Glaser GE, Mannel RS, Disaia PJ Journal of Clinical Oncology 2022 Dec 40 4119-4128 -
Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study
Casablanca Y, Wang G, Lankes HA, Tian C, Bateman NW, Miller CR, Chappell NP, Havrilesky LJ, Wallace AH, Ramirez NC, Miller DS, Oliver J, Mitchell D, Litzi T, Blanton BE, Lowery WJ, Risinger JI, Hamilton CA, Phippen NT, Conrads TP, Mutch D, Moxley K, Lee RB, Backes F, Birrer MJ, Darcy KM, Maxwell GL Cancers 2022 Sep 14 -
Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L JNCCN Journal of the National Comprehensive Cancer Network 2022 Sep 20 973-980 -
Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer
Author Collaboration S3, Makker V, Colombo N, Herráez AC, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D Journal of Bone and Joint Surgery 2022 May 77 275-276 -
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial
Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, Copeland LJ, Secord AA, Mutch DG, Santin A, Warshal DP, Spirtos NM, DiSilvestro PA, Ioffe OB, Miller DS Journal of Clinical Oncology 2022 Mar 40 968-977 -
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study
Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL, Copeland LJ, Miller DS, Coleman RL Gynecologic oncology 2022 Mar 164 481-491 -
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study
Matulonis UA, Huang HQ, Filiaci VL, Randall M, DiSilvestro PA, Moxley KM, Fowler JM, Powell MA, Spirtos NM, Tewari KS, Richards WE, Nakayama JM, Mutch DG, Miller DS, Matei D, Wenzel LB Gynecologic oncology 2022 Feb 164 428-436 -
Lynch Syndrome Identification in Endometrial Cancer Patients: Should Universal Screening be Used for all Histologies?
Parker JE, Mauer C, Zheng W, Miller DS, Lea JS Current Women's Health Reviews 2022 Feb 18 -
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Author Collaboration ft, Makker V, Colombo N, Herráez AC, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D New England Journal of Medicine 2022 Feb 386 437-448 -
Corrigendum to “Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis” (Gynecologic Oncology (2021) 162(3) (532–538), (S0090825821005114), (10.1016/j.ygyno.2021.06.017))
Levinson K, Beavis AL, Purdy C, Rositch AF, Viswanathan A, Wolfson AH, Kelly MG, Tewari KS, McNally L, Guntupalli SR, Ragab O, Lee YC, Miller DS, Huh WK, Wilkinson KJ, Spirtos NM, Le LV, Casablanca Y, Holman LL, Waggoner SE, Fader AN Gynecologic oncology 2021 Dec 163 616-617 -
Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis
Levinson K, Beavis AL, Purdy C, Rositch AF, Viswanathan A, Wolfson AH, Kelly MG, Tewari KS, McNally L, Guntupalli SR, Ragab O, Lee YC, Miller DS, Huh WK, Wilkinson KJ, Spirtos NM, Van Le L, Casablanca Y, Holman LL, Waggoner SE, Fader AN Gynecologic oncology 2021 Sep 162 532-538 -
Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors
Aguilar M, Zhang H, Zhang M, Cantarell B, Sahoo SS, Li HD, Cuevas IC, Lea J, Miller DS, Chen H, Zheng W, Gagan J, Lucas E, Castrillon DH Journal of Pathology 2021 May 254 20-30 -
Stage IVA cervical cancer: Outcomes of disease related complications and treatment
Khulpateea BR, Paulson A, Carlson M, Miller DS, Lea J International Journal of Gynecological Cancer 2021 Apr 31 518-523 -
Sex hormones, insulin, and insulin-like growth factors in recurrence of high-stage endometrial cancer
Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherman ME, Brinton LA, Yu H, Miller DS, Ramirez NC, Lankes HA, Birrer MJ, Huang GS, Gunter MJ Cancer Epidemiology Biomarkers and Prevention 2021 Apr 30 719-726 -
Ovarian cancer, version 2.2020
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM JNCCN Journal of the National Comprehensive Cancer Network 2021 Feb 19 191-226 -
Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
Mullany S, Miller DS, Robison K, Levinson K, Lee YC, Yamada SD, Walker J, Markman M, Marin A, Mast P, diZerega G Gynecologic Oncology Reports 2020 Nov 34 -
Carboplatin and paclitaxel for advanced endometrial cancer: Final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209)
Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Huang H, Cella D, Zaino R, Fleming GF Journal of Clinical Oncology 2020 Nov 38 3841-3850 -
Current practice patterns in nodal evaluation and adjuvant treatment of advanced stage endometrioid endometrial cancer: An SGO survey
Parker JE, Miller DS, Lee J, Carlson MJ, Lococo S, Lea JS Gynecologic Oncology Reports 2020 Nov 34 -
Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma
Wright CM, LaRiviere MJ, Baron JA, Uche C, Xiao Y, Arscott WT, Anstadt EJ, Barsky AR, Miller D, LaRose MI, Landsburg DJ, Svoboda J, Nasta SD, Gerson JN, Barta SK, Chong EA, Schuster SJ, Paydar I, Maity A, Plastaras JP International Journal of Radiation Oncology Biology Physics 2020 Sep 108 178-188 -
An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275
Schink JC, Filiaci V, Huang HQ, Tidy J, Winter M, Carter J, Anderson N, Moxley K, Yabuno A, Taylor SE, Kushnir C, Horowitz N, Miller DS Gynecologic oncology 2020 Aug 158 354-360 -
Practice patterns using minimally invasive surgery for the treatment of ovarian cancer: A survey of physician members of the Society of Gynecologic Oncologists
Kremer KM, Lee J, Carlson MJ, Lococo SJ, Miller DS, Lea JS Gynecologic Oncology Reports 2020 Aug 33 -
PD-L1 Expression and CD8#x0002B;Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma
Chen H, Molberg K, Strickland AL, Castrillon DH, Carrick K, Jiang Q, Niu S, Rivera-Colon G, Gwin K, Hinson S, Lea J, Miller DS, Zheng W, Lucas E American Journal of Surgical Pathology 2020 Aug 44 1050-1060 -
Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group
Miller DS, Randall ME, Filiaci V Gynecologic oncology 2020 May 157 312-322 -
Second-line lenvatinib in patients with recurrent endometrial cancer
Vergote I, Powell MA, Teneriello MG, Miller DS, Garcia AA, Mikheeva ON, Bidzinski M, Cebotaru CL, Dutcus CE, Ren M, Kadowaki T, Funahashi Y, Penson RT Gynecologic oncology 2020 Mar 156 575-582 -
A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer
Albuquerque K, Tumati V, Lea J, Ahn C, Richardson D, Miller D, Timmerman R International Journal of Radiation Oncology Biology Physics 2020 Mar 106 464-471 -
Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Krill L, Deng W, Eskander R, Mutch D, Zweizig S, Hoang B, Ioffe O, Randall L, Lankes H, Miller DS, Birrer M Gynecologic oncology 2020 Feb 156 423-429 -
Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?
Lucas EA, Chen H, Molberg KH, Castrillon DH, Rivera Colon G, Li L, Hinson SA, Thibodeaux JD, Lea JS, Miller DS, Zheng W International Journal of Gynecological Pathology 2019 Nov 38 533-542 -
Phase III trial: Adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/ carboplatin in high-intermediate and high-risk early stage endometrial cancer
Randall ME, Filiaci V, McMeekin DS, Von Gruenigen V, Huang H, Yashar CM, Mannel RS, Kim JW, Salani R, DiSilvestro PA, Burke JJ, Rutherford T, Spirtos NM, Terada K, Anderson PR, Brewster WR, Small W, Aghajanian CA, Miller DS Journal of Clinical Oncology 2019 Jul 37 1810-1818 -
The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study
Spirtos NM, Enserro D, Homesley HD, Gibbons SK, Cella D, Morris RT, DeGeest K, Lee RB, Miller DS Gynecologic oncology 2019 Jul 154 13-21 -
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Author Collaboration Ti, Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ, Park SY, Song YS, Makarova Y, Trinidad J, Ngan HY, Aravantinos G, Nam JH, Gorbunova V, Krikunova L, Bae DS, Arija JA, Mirza MR, Zamagni C, Papandreou C, Raspagliesi F, Lisyanskaya A, Benzaquen AO, Tognon G, Ortega E, Herraez AC, Buscema J, Green A, Burger R, Sakaeva D, Sanchez AR, Ghamande S, King L, Petru E, Peen U, Takeuchi S, Ushijima K, Martin AG, Miller DS The Lancet Oncology 2019 Jun 20 862-876 -
Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer
Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM, Kim YM, Powell MA, O’Malley DM, Spirtos NM, Small W, Tewari KS, Richards WE, Nakayama J, Matulonis UA, Huang HQ, Miller DS New England Journal of Medicine 2019 Jun 380 2317-2326 -
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ The Lancet Oncology 2019 May 20 636-648 -
Reply to F. Tomao et al
Hensley ML, Enserro D, Miller DS Journal of Clinical Oncology 2019 37 936 -
The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer An Institutional Experience
Manders DB, Sims TT, Bailey A, Hwang L, Richardson DL, Miller DS, Kehoe SM, Albuquerque K, Lea JS American Journal of Clinical Oncology: Cancer Clinical Trials 2018 Dec 41 1225-1230 -
Prognostic Significance of Nodal Location and Ratio in Stage IIIC Endometrial Carcinoma among a Multi-Institutional Academic Collaboration
Mayadev J, Elshaikh MA, Christie A, Nagel C, Kennedy V, Khan N, Lea JS, Ghanem A, Miller DS, Xie X, Folkert MR, Albuquerque K American Journal of Clinical Oncology: Cancer Clinical Trials 2018 Dec 41 1220-1224 -
Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: A phase III NRG oncology/gynecologic oncology group study
Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS Journal of Clinical Oncology 2018 Nov 36 3324-3330 -
Emphasis on systemic therapy in women with pelvic bone metastasis at time of diagnosis of cervical cancer
Manders DB, Sims TT, Albuquerque K, Carlson MJ, Richardson DL, Kehoe SM, Miller DS, Lea JS American Journal of Clinical Oncology: Cancer Clinical Trials 2018 Nov 41 1137-1141 -
Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer
Palavalli Parsons LH, Roane B, Manders DB, Richardson DL, Kehoe SM, Carlson M, Miller DS, Lea JS American Journal of Clinical Oncology: Cancer Clinical Trials 2018 Oct 41 933-937 -
Third-line salvage chemotherapy for recurrent carcinoma of the cervix is associated with minimal response rate and high toxicity
Manders DB, Kehoe SM, Miller DS, Lea JS, Richardson DL American Journal of Clinical Oncology: Cancer Clinical Trials 2018 Aug 41 797-801 -
Adjuvant external radiation impacts outcome of pelvis-limited stage III endometrial carcinoma: A multi-institutional study
Albuquerque K, Folkert M, Mayadev J, Christie A, Liotta MR, Nagel C, Sevak P, Harkenrider MM, Lea JS, Hanna RK, Small WC, Miller DS, Xie XJ, Potkul RK, Elshaikh MA American Journal of Clinical Oncology: Cancer Clinical Trials 2018 Aug 41 792-796 -
Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer
Conrad LB, Awdeh H, Acosta-Torres S, Conrad SA, Bailey AA, Miller DS, Lea JS Journal of Surgical Oncology 2018 Apr 117 1020-1028 -
Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis
Woldu SL, Ci B, Hutchinson RC, Krabbe LM, Singla N, Passoni NM, Clinton TN, Raj G, Miller DS, Sagalowsky AI, Lotan Y, Xie Y, Margulis V, Bagrodia A Urologic Oncology: Seminars and Original Investigations 2018 Apr 36 159.e7-159.e17 -
Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study
Felix AS, Brasky TM, Cohn DE, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel C, Boggess JF, Pearl ML, Ioffe OB, Deng W, Miller DS, Brinton LA International Journal of Cancer 2018 Mar 142 1102-1115 -
Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses
Woldu SL, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, Krabbe LM, Passoni NM, Raj G, Miller DS, Amatruda JF, Sagalowsky AI, Lotan Y, Arriaga YE, Margulis V, Bagrodia A Urology 2018 Feb 112 103-111 -
Adenocarcinoma of the uterine corpus
Creasman WT, Miller DS 2018 121-154.e8 -
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer
Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ Gynecologic oncology 2018 Jan 148 174-180 -
Locally Advanced Cervical Cancer: Outcomes with Variable Adherence to Treatment
Manders DB, Morón A, McIntire D, Miller DS, Richardson DL, Kehoe SM, Albuquerque KV, Lea JS American Journal of Clinical Oncology: Cancer Clinical Trials 2018 41 447-451 -
Long-Term Percutaneous Nephrostomy Management of Malignant Urinary Obstruction: Estimation of Optimal Exchange Frequency and Estimation of the Financial Impact of Patient Compliance
McDevitt JL, Acosta-Torres S, Zhang N, Hu T, Odu A, Wang J, Xi Y, Lamus D, Miller DS, Pillai AK Journal of Vascular and Interventional Radiology 2017 Jul 28 1036-1042.e8 -
Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol
Creasman WT, Ali S, Mutch DG, Zaino RJ, Powell MA, Mannel RS, Backes FJ, DiSilvestro PA, Argenta PA, Pearl ML, Lele SB, Guntupalli SR, Waggoner S, Spirtos N, Boggess JF, Edwards RP, Filiaci VL, Miller DS Gynecologic oncology 2017 Jun 145 519-525 -
Response to “Towards implementation of sexual healthcare”
Bedell S, Manders D, Miller D, Lea J, Kehoe S, Richardson D, Carlson M Gynecologic Oncology Reports 2017 May 20 139 -
Sparse feature selection for classification and prediction of metastasis in endometrial cancer
Ahsen ME, Boren TP, Singh NK, Misganaw B, Mutch DG, Moore KN, Backes FJ, McCourt CK, Lea JS, Miller DS, White MA, Vidyasagar M BMC Genomics 2017 Mar 18 -
The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment
Bedell S, Manders D, Kehoe S, Lea J, Miller D, Richardson D, Carlson M Gynecologic Oncology 2017 Mar 144 586-591 -
Patients with endometrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery
Miller DS Cancer 2017 Jan 123 192-196 -
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis
Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB Gynecologic oncology 2016 Nov 143 294-301 -
Sparse feature selection for classification and prediction of metastasis in endometrial cancer
Ahsen ME, Boren TP, Singh NK, Misganaw B, Lea JS, Miller DS, White MA, Vidyasagar M 2016 Oct 522-524 -
Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia
Osborne RJ, Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, Spirtos NM, Chan JK, Tidy JA, Miller DS Obstetrics and gynecology 2016 Sep 128 535-542 -
Factors influencing primary treatment of midline vulvar cancers
Conrad LB, Conrad SA, Miller DS, Richardson DL, Kehoe S, Lea JS Gynecologic oncology 2016 Jul 142 133-138 -
LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment
Peña CG, Nakada Y, Saatcioglu HD, Aloisio GM, Cuevas I, Zhang S, Miller DS, Lea JS, Wong KK, DeBerardinis RJ, Amelio AL, Brekken RA, Castrillon DH Journal of Clinical Investigation 2015 Nov 125 4063-4076 -
Ovarian involvement in endometrioid adenocarcinoma of uterus
Lin KY, Miller DS, Bailey AA, Andrews SJ, Kehoe SM, Richardson DL, Lea JS Gynecologic oncology 2015 Sep 138 532-535 -
Outcomes of treatment of gestational trophoblastic neoplasia in a primarily indigent urban population
Davidson BA, Nagel CI, Richardson DL, Kehoe SM, Miller DS, Lea JS Journal of Reproductive Medicine 2015 Jun 60 243-248 -
Surgical and systemic management of endometrial cancer: an international survey
Fotopoulou C, Kraetschell R, Dowdy S, Fujiwara K, Yaegashi N, Larusso D, Casado A, Mahner S, Herzog TJ, Kehoe S, Vergote I, Miller DS, Marth C, Fujii S, Sehouli J Archives of Gynecology and Obstetrics 2015 Apr 291 897-905 -
Reply to W.A.A. Tjalma and J.S. Grossman
Monk BJ, Miller DS, Tewari KS Journal of Clinical Oncology 2015 Mar 33 966 -
A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
Dizon DS, Sill MW, Schilder JM, McGonigle KF, Rahman Z, Miller DS, Mutch DG, Leslie KK Gynecologic oncology 2014 Dec 135 441-445 -
Adnexal masses requiring surgical intervention in women with advanced cervical cancer
Nagel CI, Thomas SK, Richardson DL, Kehoe SM, Miller DS, Lea JS Gynecologic oncology 2014 Sep 134 552-555 -
Factors associated with clinical trial screening failures in gynecologic oncology
Manders DB, Paulsen A, Richardson DL, Kehoe SM, Miller DS, Lea JS Gynecologic oncology 2014 Sep 134 450-454 -
Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: A limited access phase II trial of the Gynecologic Oncology Group
Miller DS, Blessing JA, Ramondetta LM, Pham HQ, Tewari KS, Landrum LM, Brown J, Mannel RS Journal of Clinical Oncology 2014 Sep 32 2744-2749 -
Malignant ovarian germ cell tumor - Role of surgical staging and gonadal dysgenesis
Lin KY, Bryant S, Miller DS, Kehoe SM, Richardson DL, Lea JS Gynecologic oncology 2014 Jul 134 84-89 -
The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American society for radiation oncology evidence-based guideline
Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, Fleming G, Gaffney D, Greven K, Lu K, Miller D, Moore D, Petereit D, Schefter T, Small W, Yashar C, Viswanathan AN Practical Radiation Oncology 2014 May 4 137-144 -
A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study
Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM Gynecologic oncology 2012 Dec 127 456-461 -
Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement
Boren T, Lea J, Kehoe S, Miller DS, Richardson D Gynecologic oncology 2012 Oct 127 43-46 -
Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma?
Garcia-Soto AE, Boren T, Wingo SN, Heffernen T, Miller DS American journal of obstetrics and gynecology 2012 Mar 206 242.e1-242.e5 -
Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy
Boren TP, Carrick K, Kehoe SM, Lea J, Miller DS, Richardson DL Gynecologic oncology 2012 Mar 124 508-511 -
Adenocarcinoma of the Uterine Corpus
Creasman WT, Miller DS 2012 Mar 141-174 -
PRO: All patients with serous and clear cell carcinomas of the endometrium should receive chemotherapy as part of their treatment
Boren TP, Miller DS Clinical Ovarian Cancer 2011 Dec 4 106-110 -
The role of lymphadenectomy in endometrial cancer
Kehoe SM, Miller DS Clinical Obstetrics and Gynecology 2011 Jun 54 235-244 -
A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study
Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS Gynecologic oncology 2011 Apr 121 118-121 -
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A gynecologic oncology group study
Osborne RJ, Filiaci V, Schink JC, Mannel RS, Secord AA, Kelley JL, Provencher D, Miller DS, Covens AL, Lage JM Journal of Clinical Oncology 2011 Mar 29 825-831 -
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A gynecologic oncology group study
Osborne RJ, Filiaci V, Schink JC, Mannel RS, Secord AA, Kelley JL, Provencher D, Miller DS, Covens AL, Lage JM Journal of Clinical Oncology 2011 Mar 29 825-831 -
Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
Boren TP, Miller DS Women's Health 2010 Nov 6 789-795 -
PRO: All patients with serous and clear cell carcinomas of the endometrium should receive chemotherapy as part of their treatment
Boren TP, Miller DS Clinical Ovarian Cancer 2010 Nov 3 74-78 -
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A gynecologic oncology group trial
Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J International Journal of Gynecological Cancer 2010 Oct 20 1137-1141 -
An update on endometrial cancer
Boren T, Miller D Texas Medicine 2010 Sep 106 50-55 -
Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas
Huang YW, Luo J, Weng YI, Mutch DG, Goodfellow PJ, Miller DS, Huang TH Gynecologic oncology 2010 May 117 239-247 -
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer
Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, Huang TH Cancer research 2009 Dec 69 9038-9046 -
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology
Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, Krasner CN Gynecologic oncology 2009 Dec 115 443-446 -
Pharmacotherapy of endometrial cancer
Barrena Medel NI, Bansal S, Miller DS, Wright JD, Herzog TJ Expert Opinion on Pharmacotherapy 2009 Aug 10 1939-1951 -
Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH Journal of Clinical Oncology 2009 Jun 27 2686-2691 -
Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer
Miller DS, Fleming G, Randall ME JNCCN Journal of the National Comprehensive Cancer Network 2009 May 7 535-541 -
Somatic LKB1 mutations promote cervical cancer progression
Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge JO, Wong KK, Castrillon DH PloS one 2009 Apr 4 -
Recent progress: Gynecologic oncology group trials in uterine corpus tumors
King LP, Miller DS Reviews on Recent Clinical Trials 2009 4 70-74 -
Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group
Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO Gynecologic oncology 2008 Jul 110 65-70 -
Implications of EGFR inhibition in ovarian cancer cell proliferation
Bull Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang LL, Miller DS, Lea JS Gynecologic oncology 2008 Jun 109 411-417 -
Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix
Bull-Phelps SL, Garner EI, Walsh CS, Gehrig PA, Miller DS, Schorge JO Gynecologic oncology 2007 Nov 107 316-319 -
Simplifying the preevacuation testing strategy for patients with molar pregnancy
Knowles LM, Drake RD, Ashfaq R, Castrillon DH, Miller DS, Schorge JO Journal of Reproductive Medicine for the Obstetrician and Gynecologist 2007 Aug 52 685-688 -
Silencing of HPV 18 oncoproteins with RNA interference causes growth inhibition of cervical cancer cells
Lea JS, Sunaga N, Sato M, Kalahasti G, Miller DS, Minna JD, Muller CY Reproductive Sciences 2007 Jan 14 20-28 -
Gestational trophoblastic disease among Hispanic women: A 21-year hospital-based study
Drake RD, Rao GG, McIntire DD, Miller DS, Schorge JO Gynecologic oncology 2006 Oct 103 81-86 -
Advanced endometrial cancer: Is lymphadenectomy necessary or sufficient?
Scott Miller D Gynecologic oncology 2006 May 101 191-193 -
Retrospective cohort study of surgical staging for ovarian low malignant potential tumors
Wingo SN, Knowles LM, Carrick KS, Miller DS, Schorge JO American journal of obstetrics and gynecology 2006 May 194 e20-e22 -
Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
Long HJ, Monk BJ, Huang HQ, Grendys EC, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV Gynecologic oncology 2006 Mar 100 537-543 -
Hormonal therapy in epithelial ovarian cancer
Rao GG, Miller DS Expert Review of Anticancer Therapy 2006 6 43-47 -
Ovarian preservation in stage I low-grade endometrial stromal sarcomas
Li AJ, Giuntoli RL, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller DS, Karlan BY Obstetrics and gynecology 2005 Dec 106 1304-1308 -
Fertility-sparing surgery for ovarian low malignant potential tumors
Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JW Obstetrical and Gynecological Survey 2005 Dec 60 797-798 -
Fertility-sparing surgery for ovarian low malignant potential tumors
Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO Gynecologic oncology 2005 Aug 98 263-266 -
Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study
Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC Gynecologic oncology 2005 Aug 98 217-221 -
Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles
Lavie I, Rao GG, Castrillon DH, Miller DS, Schorge JO American journal of obstetrics and gynecology 2005 May 192 1362-1364 -
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: A Gynecologic Oncology Group study
Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh N Gynecologic oncology 2005 Mar 96 810-817 -
Clinical applications of hormonal therapy in ovarian cancer
Rao GG, Miller DS Current treatment options in oncology 2005 Mar 6 97-102 -
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
Long HJ, Bundy BN, Grendys EC, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Mackey D Journal of Clinical Oncology 2005 23 4626-4633 -
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study
Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R Gynecologic oncology 2005 Jan 96 67-71 -
Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies
Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL Gynecologic oncology 2004 Aug 94 320-324 -
Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development
Lea JS, Ashfaq R, Muneer S, Burbee DG, Miller DS, Minna JD, Muller CY Journal of the Society for Gynecologic Investigation 2004 Jul 11 329-337 -
Other primary malignancies in patients with uterine corpus malignancy
Delin JB, Miller DS, Coleman RL American journal of obstetrics and gynecology 2004 May 190 1429-1431 -
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer
Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC Clinical Cancer Research 2004 May 10 3474-3478 -
P16 as a molecular biomarker of cervical adenocarcinoma
Schorge JO, Lea JS, Elias KJ, Rajanbabu R, Coleman RL, Miller DS, Ashfaq R American journal of obstetrics and gynecology 2004 Mar 190 668-673 -
Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis
Lea JS, Coleman R, Kurien A, Schorge JO, Miller DS, Minna JD, Muller CY American journal of obstetrics and gynecology 2004 Mar 190 674-679 -
Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A Gynecologic oncology 2004 Feb 92 639-643 -
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF Journal of Clinical Oncology 2004 22 3113-3119 -
Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma
Lea JS, Coleman RL, Garner EO, Duska LR, Miller DS, Schorge JO Gynecologic oncology 2003 Dec 91 558-562 -
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: A gynecologic oncology group study
Scott Miller D, Blessing JA, Lentz SS, Scott McMeekin D, Mackey D Cancer 2003 Oct 98 1664-1669 -
Management of Low-Risk Gestational Trophoblastic Neoplasia in Indigent Women
Schorge JO, Lea JS, Farrar DF, King MR, Coleman RL, Miller DS Journal of Reproductive Medicine for the Obstetrician and Gynecologist 2003 Oct 48 780-784 -
Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy: A case report and review of the literature
Jaiswal VR, Baird J, Fleming J, Miller DS, Sharma S, Molberg K Archives of Pathology and Laboratory Medicine 2003 Jul 127 879-882 -
Postmolar surveillance at a trophoblastic disease center that serves indigent women
Allen JE, King MR, Farrar DF, Miller DS, Schorge JO American journal of obstetrics and gynecology 2003 May 188 1151-1153 -
Cervical adenocarcinoma survival among Hispanic and white women: A multicenter cohort study
Schorge JO, Lea JS, Garner EO, Duska LR, Miller DS, Coleman RL American journal of obstetrics and gynecology 2003 Mar 188 640-644 -
Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: A Gynecologic Oncology Group study
Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J Gynecologic oncology 2002 85 507-510 -
Urinary bladder cancer
Wai CY, Miller DS Clinical Obstetrics and Gynecology 2002 45 844-854 -
Stage IIB-IVB cervical adenocarcinoma: Prognostic factors and survival
Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, Schorge JO Gynecologic oncology 2002 84 115-119 -
Early-stage cervical adenocarcinoma treated by surgical intent: The role of para-aortic lymph node dissection
Lea JS, Sheets EE, Duska LR, Miller DS, Schorge JO Gynecologic oncology 2002 84 285-288 -
A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A gynecologic oncology group study
Miller DS, Blessing JA, Lentz SS, Waggoner SE, Mackey D Gynecologic oncology 2002 87 247-251 -
Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ
Lea JS, Shin CH, Sheets EE, Coleman RL, Gehrig PA, Duska LR, Miller DS, Schorge JO Gynecologic oncology 2002 87 129-132 -
Should we offer HRT to ovarian and endometrial cancer survivors? Yes. There is no scientifically valid reason not to do so
Miller DS Emergency Medicine 2001 Sep 46 31-32+34 -
Optimum screening interventions for gynecologic malignancies.
Lea JS, Miller DS Texas medicine 2001 Feb 97 49-55 -
Rectovaginal fistula and rectal injury
Miller DS Operative Techniques in Gynecologic Surgery 2001 6 86-94 -
Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer
Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE Gynecologic oncology 2001 83 383-387 -
Bacteriology and treatment of malodorous lower reproductive tract in gynecologic cancer patients
Von Gruenigen VE, Coleman RL, Li AJ, Heard MC, Miller DS, Hemsell DL Obstetrics and gynecology 2000 Jul 96 23-27 -
Adenomyofibroma of the endometrium with skeletal muscle differentiation
Sinkre P, Miller DS, Milchgrub S, Hameed A International Journal of Gynecological Pathology 2000 Jul 19 280-283 -
Uterine metastasis from a heterologous metaplastic breast carcinoma simulating a primary uterine malignancy
Sinkre P, Milchgrub S, Miller DS, Albores-Saavedra J, Hameed A Gynecologic oncology 2000 Apr 77 216-218 -
Ectopic production and localization of β-human chorionic gonadotropin in lymphoepithelioma-like carcinoma of the cervix: A case report
Coleman RL, Lindberg G, Muller CY, Miller DS, Hameed A International Journal of Gynecological Pathology 2000 Apr 19 179-182 -
Endometrial endometrioid carcinomas associated with Ewing sarcoma/peripheral primitive neuroectodermal tumor
Sinkre P, Albores-Saavedra J, Miller DS, Copeland LJ, Hameed A International Journal of Gynecological Pathology 2000 Apr 19 127-132 -
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: A Gynecologic Oncology Group study
Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L American Journal of Clinical Oncology: Cancer Clinical Trials 2000 23 355-357 -
Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: A pilot study
O'Boyle JD, Coleman RL, Bernstein SG, Lifshitz S, Muller CY, Miller DS Gynecologic oncology 2000 79 238-243 -
Chromosome 4 deletions are frequent in invasive cervical cancer and differ between histologic variants
Sherwood JB, Shivapurkar N, Lin WM, Ashfaq R, Miller DS, Gazdar AF, Muller CY Gynecologic oncology 2000 79 90-96 -
Role of TSG101 in uterine cervix cancer
O'Boyle JD, Proctor ML, Fong KM, Lin WM, Miller DS, Muller CY Gynecologic oncology 1999 Dec 75 401-405 -
The ovarian tumor index predicts risk for malignancy
Twickler DM, Forte TB, Santos-Ramos R, McIntire D, Harris P, Miller DS Cancer 1999 Dec 86 2280-2290 -
Abdominal compartment syndrome in gynecologic surgery
Von Gruenigen VE, Coleman RL, King MR, Miller DS Obstetrics and gynecology 1999 Nov 94 830-832 -
Frequent expression of β-human chorionic gonadotropin (β-hCG) in squamous cell carcinoma of the cervix
Hameed A, Miller DS, Muller CY, Coleman RL, Albores-Saavedra J International Journal of Gynecological Pathology 1999 Oct 18 381-386 -
Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas
Flowers LC, Wistuba II, Scurry J, Muller CY, Ashfaq R, Miller DS, Minna JD, Gazdar AF Journal of the Society for Gynecologic Investigation 1999 Jul 6 213-221 -
Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer
Von Gruenigen VE, O'Boyle JD, Coleman RL, Wilson D, Miller DS, Mathis JM International Journal of Gynecological Cancer 1999 9 365-372 -
Does glutamine supplementation increase radioresistance in squamous cell carcinoma of the cervix?
Santoso JT, Lucci JA, Coleman RL, Hatch S, Wong P, Miller D, Mathis JM Gynecologic oncology 1998 Dec 71 359-363 -
In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer
Von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM Gynecologic oncology 1998 Jun 69 197-204 -
Pathology slide review in gynecologic oncology
Santoso JT, Coleman RL, Voet RL, Bernstein SG, Lifshitz S, Miller D Obstetrics and gynecology 1998 May 91 730-734 -
Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: Association with human papillomavirus type
Muller CY, O'Boyle JD, Fong KM, Wistuba II, Biesterveld E, Ahmadian M, Miller DS, Gazdar AF, Minna JD Journal of the National Cancer Institute 1998 Mar 90 433-439 -
Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers
Thai TH, Du F, Tsan JT, Jin Y, Phung A, Spillman MA, Massa HF, Muller CY, Ashfaq R, Mathis JM, Miller DS, Trask BJ, Baer R, Bowcock AM Human molecular genetics 1998 Feb 7 195-202 -
Topotecan in the treatment of gynecologic cancer.
Coleman RL, Miller DS Seminars in oncology 1997 Dec 24 S20-55-S20-5563 -
Topotecan in the treatment of gynecologic cancer
Coleman RL, Miller DS Seminars in oncology 1997 Dec 24 S2055-S2063 -
Applying gene therapy to ovarian cancer
Von Gruenigen VE, Muller CY, Miller DS, Mathis JM Contemporary Ob-Gyn 1997 Feb 42 113-124 -
Preinvasive and invasive breast and cervical cancer prior to or during pregnancy
Shivvers SA, Miller DS Clinics in Perinatology 1997 24 369-390 -
Multicystic ovarian tumor weighing 156 lbs: the second largest tumor in Texas.
Tait DL, Miller DS Texas medicine 1997 Jan 93 89-91 -
Immunologic characterization of tumor markers in human ovarian cancer cell lines
Kutteh WH, Miller DS, Mathis JM Journal of the Society for Gynecologic Investigation 1996 Jul 3 216-222 -
Long-term results of interstitial implant in locally advanced cervical cancer: A retrospective study of 50 cases
Nguyen PD, John B, Carmody TJ, Huang K, Miller DS Radiation Oncology Investigations 1996 4 33-40 -
Adenovirus-Based p53 gene therapy in ovarian cancer
SANTOSO JT, TANG DC, LANE SB, HUNG J, REED DJ, MULLER CY, CARBONE DP, LUCCIIII JA, SCOTTMILLER D, MATHIS MJ Gynecologic oncology 1995 Nov 59 171-178 -
Transfusion medicine in obstetrics and gynecology
Santoso JT, Lin DW, Miller DS Obstetrical and Gynecological Survey 1995 Jun 50 470-481 -
The effect of naproxen on fever in patients with advanced gynecologic malignancies
Economos K, Lucci JA, Richardson B, Yazigi R, Miller DS Gynecologic oncology 1995 Feb 56 250-254 -
CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors
Bulun SE, Economos K, Miller D, Simpson ER Journal of Clinical Endocrinology and Metabolism 1994 Dec 79 1831-1834 -
Schistosomiasis and cervical cancer in Ghana
Szela E, Bachicha J, Miller D, Till M, Wilson JB International Journal of Gynecology and Obstetrics 1993 Aug 42 127-130 -
DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases
Coleman RL, Schink JC, Miller DS, Bauer KD, August CZ, Rademaker AW, Lurain JR Gynecologic oncology 1993 Jul 50 20-24 -
Flow cytometric evaluation of early invasive cervical cancer
Connor JP, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR Obstetrics and gynecology 1993 Mar 81 367-371 -
Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease
Schink JC, Singh DK, Rademaker AW, Miller DS, Lurain JR Obstetrics and gynecology 1992 Nov 80 817-820 -
A Phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma: A Gynecologic Oncology Group study
Miller DS, Brady MF, Barrett RJ American Journal of Clinical Oncology: Cancer Clinical Trials 1992 15 125-128 -
Critical reassessment of second‐look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer
Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero OM, Teng NN Cancer 1992 Jan 69 502-510 -
The role of contraception in the development of postmolar gestational trophoblastic tumor
Deicas RE, Miller DS, Rademaker AW, Lurain JR Obstetrics and gynecology 1991 Aug 78 221-226 -
Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium
Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Miller DS Obstetrics and gynecology 1991 Jul 78 63-69 -
Tumor size in endometrial cancer
Schink JC, Rademaker AW, Miller DS, Lurain JR Cancer 1991 Jun 67 2791-2794 -
Quantitative protein changes in metastatic versus primary epithelial ovarian carcinoma
Lawson SR, Latter G, Miller DS, Goldstein D, Naps M, Burbeck S, Teng NN, Zuckerkandl E Gynecologic oncology 1991 Apr 41 22-27 -
Dual-parameter flow cytometric analysis coupling the measurements of forward-angle light scatter and DNA content of archival ovarian carcinomas of low malignant potential
Eriksen B, Miller DS, Murad TM, Lurain JR, Bauer KD Analytical and Quantitative Cytology and Histology 1991 13 45-53 -
Prognostic factors in gestational trophoblastic tumors: A proposed new scoring system based on multivariate analysis
Lurain JR, Casanova LA, Miller DS, Rademaker AW American journal of obstetrics and gynecology 1991 164 611-616 -
Study of the selective cytotoxic properties of cationic, lipophilic mitochondrial-specific compounds in gynecologic malignancies
Christman JE, Miller DS, Coward P, Smith LH, Teng NN Gynecologic oncology 1990 Oct 39 72-79 -
Correspondence
Schink JC, Miller DS, Lurain JR Gynecologic oncology 1990 Aug 38 294 -
Flow cytometric evaluation of epithelial ovarian cancer
Barnabei VM, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR American journal of obstetrics and gynecology 1990 Jun 162 1584-1592 -
Letter to the editor
Schink JC, Miller DS, Lurain JR Gynecologic oncology 1990 38 294 -
Endocrinologic aspects of gestational trophoblastic diseases
Miller DS, Seifer DB International journal of fertility 1990 35 137-153 -
Classification and staging of gestational trophoblastic tumors
Miller DS, Lurain JR Obstetrics and gynecology clinics of North America 1988 15 477-490 -
Epithelial ovarian carcinoma in patients with intersex disorders: The role of pituitary gonadotropins in ovarian tumorigenesis
Miller DS, Teng NN, Ballon SC Gynecologic oncology 1986 Jul 24 299-308 -
A critical reassessment of second‐look laparotomy in epithelial ovarian carcinoma
Miller DS, Ballon SC, Teng NN, Seifer DB, Soriero OM Cancer 1986 Feb 57 530-535 -
Psychosocial Variables and the Course of Cancer
Funch DP, Fiore NA, Vitaliano PP, Lipscomb PA, Carr JE, Levy SM, Winkelstein A, Rabin BS, Lippman M, Cohen S, Cassileth BR, Miller DS, Miller C, Lusk EJ, Brown L New England Journal of Medicine 1985 Nov 313 1354-1356 -
Psychosocial Correlates of Survival in Advanced Malignant Disease?
Cassileth BR, Lusk EJ, Miller DS, Brown LL, Miller C New England Journal of Medicine 1985 Jun 312 1551-1555 -
A psychological analysis of cancer patients and their next‐of‐kin
Cassileth BR, Lusk EJ, Strouse TB, Miller DS, Brown LL, Cross PA Cancer 1985 Jan 55 72-76 -
Prognostic factors in second-look laparotomy for epithelial ovarian carcinoma
Miller DS, Ballon SC, Soriero OM Surgical forum 1985 VOL. 36 462-463 -
Psychosocial Status in Chronic Illness
Bergsagel PL, Finucane TE, Meenan RF, Mason JH, Kazis LE, Hürny C, Holland JC, Barofsky I, Bloom JR, Cassileth BR, Lusk EJ, Strouse TB, Miller DS, Brown LL, Cross PA, Tenagila AN New England Journal of Medicine 1984 Dec 311 1580-1582 -
Psychosocial Status in Chronic Illness: A Comparative Analysis of Six Diagnostic Groups
Cassileth BR, Lusk EJ, Strouse TB, Miller DS, Brown LL, Cross PA, Tenaglia AN New England Journal of Medicine 1984 Aug 311 506-511 -
Pulsatile administration of low-dose gonadotropin-releasing hormone. Ovulation and pregnancy in women with hypothalamic amenorrhea
Miller DS, Reid RR, Cetel NS, Rebar RW, Yen SS Obstetrical and Gynecological Survey 1984 May 39 296-297 -
Pulsatile Administration of Low-Dose Gonadotropin-Releasing Hormone: Ovulation and Pregnancy in Women With Hypothalamic Amenorrhea
Miller DS, Reid RR, Cetel NS, Rebar RW, Yen SS JAMA: The Journal of the American Medical Association 1983 Dec 250 2937-2941 -
The use of the laser in gynecology.
Miller DS The Journal of the South Carolina Medical Association 1983 Nov 79 627-630 -
Pulsatile administration of low-dose gonadotropin-releasing hormone. Ovulation and pregnancy in women with hypothalamic amenorrhea
Miller DS, Reid RR, Cetel NS, Rebar RW, Yen SS Journal of the American Medical Association 1983 250 2937-2941 -
Attitudes Toward Clinical Trials Among Patients and the Public
Cassileth BR, Lusk EJ, Miller DS, Hurwitz S JAMA: The Journal of the American Medical Association 1982 Aug 248 968-970
-
Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma
Research
- Reconstructive pelvic surgery
- Gynecologic oncology
- Clinical trials
- Antineoplastic drug development
Clinical Focus
- Gynecologic Cancers
- Surgical Treatment for Gynecologic Cancer
- Medical Treatment of Gynecologic Cancer
- Ovarian Cancer
- Peritoneal Cancer
- Gestational Trophoblastic Disease
- Endometrial Cancer
- Uterine Cancer
- Cervical Cancer
- Vulvar Cancer
- Vaginal Cancer
Q&A by Dr. Miller
Articles by Dr. Miller
Results: 1 Locations
Gynecologic Oncology Clinic
at Cancer Care Outpatient Building 6202 Harry Hines Blvd., 4th FloorDallas, Texas 75235 (214) 645-4673 Directions to Gynecologic Oncology Clinic at Cancer Care Outpatient Building, Dallas Parking Info for Gynecologic Oncology Clinic